United Kingdom Cancer Diagnostics Market By Product (Consumables v/s Instruments), By Technology (IVD Testing, Imaging, Biopsy), By Application (Breast Cancer, Lung Cancer, Colorectal Cancer, Others), By End User (Hospitals & Clinics, Diagnostic Laboratories, Others), By Region, Competition Forecast & Opportunities, 2027

United Kingdom cancer diagnostics market is anticipated to witness a robust CAGR in the forecast period, 2023-2027. The market is driven by the surge in occurrence and prevalence of cancer and the technological advancements in cancer diagnostic technology. Supportive government initiatives and the strong healthcare infrastructure of the country are further expected to fuel the United Kingdom cancer diagnostics market growth over the next five years.

Increased Prevalence of Cancer Drives the Market Growth

Cancer is a condition in which cells in a particular part of the body grow uncontrollably. The cancerous cell can enter and destroy surrounding tissue, including organs. It generally originates in one part of the part before spreading into the whole body and the process is known as metastasis. According to a study by National Health Service, one in two will develop some kind of cancer in their entire lifetime, which shows it is highly prevalent across the country. The four most common types of cancer occurring in the United Kingdom are lung cancer, prostate cancer, bowel cancer, and breast cancer. Growing health-consciousness among people is making them opt for regular health check-ups. Cancer diagnostics laboratories witness a large number of patients who come to check if there is any presence of cancerous cells in the body as a preventive measure. Also, the rise in the disposable income of middle-class families is improving the quality of healthcare services they are able to afford and is expected to boost the demand for cancer diagnostics services in the country over the next five years.

Favorable Government Policies Fuels the Market Growth

The government of the United Kingdom has set a 10-year cancer plan for England. The NHS long term plan was made and published in 2019, and at that time, the cancer survival rate was the highest in the previous years. National Health Service (NHS) is taking every possible measure to improve cancer survival, and cancer diagnosis is a priority for the government. Patients diagnosed with early stages of cancer that are at stage 1 and stage 2 have the best chance for survival. The long-term plan has set a target that by 2028, the number of cancers diagnosed at stage 1 and stage 2 will grow from half to three-quarters of cancer, which means that 55,000 patients will survive cancer for at least five years after diagnosis. The plan is expected to improve the patient experience outcome and quality of life of patients. It is expected to lower the variation and inequalities in cancer treatment. Therefore, the announcement of initiatives and plans by the government to lower the mortality rate of cancer and enhance the chances of survival from cancer is expected to fuel the growth of the United Kingdom cancer diagnostics market in the next five years.

Booming Healthcare Infrastructure Supports the Market Growth

The permanent residents of the United Kingdom are entitled to free healthcare services through the National Healthcare Service. Also, the patients can avail of private health insurance services to have quicker access to better facilities, less waiting time, and skilled healthcare professionals. Each region of the United Kingdom has its own National Healthcare Service body, and the Department of Health oversees it. National Healthcare Service provides a number of services to women residents. They can be accessed through well woman clinics as they offer services for screening for cervical and breast cancer. The supportive healthcare system and the rise in the number of patients availing of public facilities are expected to propel the United Kingdom cancer diagnostics market over the forecast period.

Click here to download the sample

Market Segmentation

The United Kingdom cancer diagnostics market is segmented into product, technology, application, end user, regional distribution, and competitive landscape. Based on product, the market is bifurcated into consumables and instruments. Based on technology, the market is divided into IVD testing, imaging, and biopsy. Based on application, the market is divided into breast cancer, lung cancer, colorectal cancer, and others. Based on end user, the market is divided into hospitals & clinics, diagnostic laboratories, and others. The United Kingdom cancer diagnostics market is studied in major regions namely London, Southeast, East Anglia, Scotland, Southwest, East Midlands, Yorkshire & Humberside, and rest of United Kingdom.

Market Players

GE Healthcare UK Limited, Becton, Dickinson U.K. Limited, Roche Diagnostics UK, Abbott Laboratories Limited, Fujifilm Healthcare UK Limited, Hologic (UK) Limited, Agilent Technologies UK Limited, are the major market players operating in the United Kingdom cancer diagnostics market.